浩欧博公告，第三季度营收为1.03亿元，同比下降1.64%；净利润为1402万元，同比增长113.01%。前三 季度营收为2.92亿元，同比下降4.84%；净利润为2618.92万元，同比下降1.41%。 ...

10月23日，浩欧博跌5.11%，截至发稿，报148.07元/股，成交7434.69万元，换手率0.77%，总市值93.99 亿元。 截至发稿，姚宏福累计任职时间3年98天，现任基金资产总规模1.33亿元，任职期间最佳基金回 报-31.23%， 任职期间最差基金回报-32.27%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，申万菱信基金旗下1只基金重仓浩欧博。申万菱信医药先锋股票A（005433）二季度持有股 数5.61万股，占基金净值比例为5.74%，位居第六大重仓股。根据测算，今日浮亏损失约44.75万元。 责任编辑：小浪快报 申万菱信医药先锋股票A（005433）成立日期2020年11月16日，最新规模1.2亿。今年以来亏损7%，同 类排名4215/4218；近一年亏损10.41%，同类排名3867/3875；成立以来亏损49.92%。 资料显示，江苏浩欧博生物医药股份有限公司位于苏州工业园区东堰里路9号，成立日期2009年6月 ...

Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. has seen a stock price increase of 5.1%, reaching 169.21 yuan per share, with a total market capitalization of 10.741 billion yuan [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include sales from other products at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] Group 2 - From the perspective of major fund holdings, one fund under Nuoan Fund has heavily invested in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, representing 5.9% of the fund's net value [2] - The fund has achieved a year-to-date return of 51% and a one-year return of 57.74%, ranking 453 out of 8,026 in its category [2] - The fund manager, Li Yuliang, has a tenure of over 10 years, with the best fund return during his management being 193.95% [2]

Group 1 - Haobio signed a framework agreement with Roche Diagnostics for the procurement of chemiluminescent antibody detection products, which will enhance brand recognition and market share in China, although the agreement does not specify financial details and may have limited impact on stock price [1] - Chengda Bio entered into a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious disease prevention, which is expected to synergize with existing vaccine development platforms [2] - Shengxiang Bio plans to invest 20 million yuan in a fund aimed at innovative healthcare startups, aligning with its strategic development and investment direction [3] Group 2 - China National Pharmaceutical Group reported a revenue of approximately 39.38 billion yuan and a net profit of about 1.49 billion yuan for the first three quarters of 2025, reflecting a slight increase in both metrics despite industry competition [4] - Puluo Pharmaceutical announced a revenue of approximately 7.76 billion yuan and a net profit of about 700 million yuan for the first three quarters of 2025, indicating a decline in performance due to pressures in the formulation and raw material drug sectors, with expectations for gradual recovery next year [5]

Core Viewpoint - The signing of the cooperation framework agreement between Haobor and Roche Diagnostics is a significant step in implementing the company's long-term development strategy, aimed at enhancing brand recognition and expanding market share in the diagnostic reagent field [1]. Group 1: Partnership Details - Haobor has entered into a cooperation framework agreement with Roche Diagnostics (Shanghai) Co., Ltd. to collaborate in the field of chemiluminescent self-antibody testing products [1]. - This partnership is expected to facilitate mutual learning and communication, allowing both companies to improve their capabilities and provide higher quality products and services to customers [1]. Group 2: Strategic Implications - The collaboration is seen as beneficial for increasing Haobor's brand recognition in the domestic market [1]. - The agreement is anticipated to positively impact Haobor's development by further expanding its market share in the diagnostic reagent sector [1].

Core Viewpoint - The signing of the framework agreement between the company and Roche Diagnostics is a significant step in implementing the company's long-term development strategy, focusing on the field of chemiluminescent self-antibody testing products [1] Group 1: Partnership Details - The framework agreement was signed on October 21, 2025, in Suzhou, and serves as a foundational and guiding document for mutual cooperation projects between the company and Roche Diagnostics [1] - The agreement does not involve specific financial amounts, indicating a focus on collaboration rather than immediate financial commitments [1] Group 2: Strategic Implications - The collaboration is expected to enhance the company's brand recognition in the domestic market, which is crucial for expanding its market share in the diagnostic reagent sector [1] - The partnership will facilitate communication and learning between the two entities, allowing the company to continuously improve its capabilities and provide higher quality products and services to customers [1]

Core Viewpoint - The signing of the cooperation framework agreement between Haobor (688656.SH) and Roche Diagnostics (Shanghai) Co., Ltd. is a significant step in implementing the company's long-term development strategy, aimed at enhancing brand recognition and expanding market share in the diagnostic reagent field [1] Group 1: Cooperation Agreement - The cooperation framework agreement focuses on the field of chemiluminescent self-antibody testing products [1] - The collaboration is expected to facilitate mutual learning and improve the quality of products and services offered to customers [1] - The agreement serves as a non-binding framework statement, meaning it does not impose legal obligations or grounds for liability for breach of contract [1] Group 2: Market Impact - The partnership is anticipated to positively impact the company's development by increasing its market presence in the domestic market [1] - The specific projects under this cooperation will require separate agreements, indicating potential uncertainties in the implementation of the collaboration [1]

Core Viewpoint - The signing of the cooperation framework agreement between Haobo (688656.SH) and Roche Diagnostics (Shanghai) Co., Ltd. is a significant step in implementing the company's long-term development strategy, aimed at enhancing brand recognition and expanding market share in the diagnostic reagent field [1][1]. Group 1 - The cooperation is expected to improve the company's brand recognition in the domestic market [1]. - The partnership will facilitate market share expansion in the diagnostic reagent sector [1]. - The collaboration aims to enhance communication and learning between the two companies, ultimately leading to better products and services for customers [1]. Group 2 - The signed framework agreement is a non-binding statement of intent and does not impose legal obligations or liability for breach of contract [1]. - Specific cooperation projects will require separate agreements, indicating a level of uncertainty regarding the implementation of the partnership [1].

证券代码：688656 证券简称：浩欧博 公告编号：2025-059 江苏浩欧博生物医药股份有限公司 关于自愿披露签订合作框架协议暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、合作协议签订情况 1 江苏浩欧博生物医药股份有限公司（以下简称"公司"）与罗氏诊断产品（上 海）有限公司（以下简称"罗氏诊断"）签署《合作框架协议》（以下简称"本 协议"），双方就化学发光自身抗体检测产品领域开展合作。 本次签署的《合作框架协议》是以双方合作意向为原则的框架性陈述，不构成 强制的法律约束，亦不构成协议双方相互追究违约责任的依据。具体合作项目 需另行签署合作协议，双方的合作能否正常实施推进存在一定的不确定性。 本次签订的《合作框架协议》不涉及具体金额和项目合作的权利义务，具体的 交易细节需要双方在后期签署的正式合同或协议中另行约定，预计不会对公司 本年度的业绩及经营成果产生重大影响。 本协议履行实施过程中可能存在受宏观经济形势、行业政策及市场环境变化等 因素影响，可能存在履行效果不达预期或者合作终止 ...

Core Viewpoint - The company Haobo (688656) has signed a framework cooperation agreement with Roche Diagnostics (Shanghai) Co., Ltd. to collaborate in the field of chemiluminescent self-antibody testing products [1] Group 1 - The agreement serves as a foundational and guiding document for mutual cooperation projects between the two companies [1]